Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Current approaches and challenges in monitoring treatment responses in breast cancer.

Graham LJ, Shupe MP, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Gallagher C, Nissan A, Henry L, Stojadinovic A, Peoples GE, Shumway NM.

J Cancer. 2014 Jan 5;5(1):58-68. doi: 10.7150/jca.7047. Review.

2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
3.

Future directions for monitoring treatment responses in breast cancer.

Shupe MP, Graham LJ, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Stojadinovic A, Peoples GE, Shumway NM.

J Cancer. 2014 Jan 5;5(1):69-78. doi: 10.7150/jca.7048. Review.

4.

Current approaches and challenges in early detection of breast cancer recurrence.

Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, Stojadinovic A, Shumway NM, Avital I, Peoples GE, Setlik RF.

J Cancer. 2014 Mar 16;5(4):281-90. doi: 10.7150/jca.8016. eCollection 2014. Review.

5.
6.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, J├Ânsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
8.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
9.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
10.

Weight changes during chemotherapy for breast cancer.

Costa LJ, Varella PC, del Giglio A.

Sao Paulo Med J. 2002 Jul 4;120(4):113-7.

11.

Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.

Ishitobi M, Komoike Y, Motomura K, Koyama H, Inaji H.

Breast J. 2010 Jan-Feb;16(1):9-13. doi: 10.1111/j.1524-4741.2009.00864.x. Epub 2009 Nov 19.

PMID:
19929889
12.

Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.

Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, Ben-Yosef R, Marmor S, Grinberg Y, Maimon N, Weinstein J, Yaal-Hahoshen N.

Clin Drug Investig. 2006;26(12):691-701.

PMID:
17274676
13.

Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).

Deo SV, Bhutani M, Shukla NK, Raina V, Rath GK, Purkayasth J.

J Surg Oncol. 2003 Dec;84(4):192-7.

PMID:
14756429
14.

Future directions for the early detection of recurrent breast cancer.

Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, Stojadinovic A, Shumway NM, Avital I, Peoples GE, Setlik RF.

J Cancer. 2014 Mar 16;5(4):291-300. doi: 10.7150/jca.8017. eCollection 2014. Review.

15.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

16.

Treatment of locally advanced and metastatic bladder cancer.

Khochikar MV.

Indian J Urol. 2008 Jan;24(1):84-94. doi: 10.4103/0970-1591.38609.

17.

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS.

Urology. 2007 Jan;69(1 Suppl):62-79. Review.

PMID:
17280909
18.

Adjuvant therapy for breast cancer.

[No authors listed]

NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. Review.

PMID:
11512506
19.

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, et al.

J Clin Oncol. 1995 Mar;13(3):547-52.

PMID:
7884414
20.
Items per page

Supplemental Content

Write to the Help Desk